Group Gp Lp Column III Sells 3,511,826 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) major shareholder Group Gp Lp Column III sold 3,511,826 shares of Tenaya Therapeutics stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $0.56, for a total value of $1,966,622.56. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, February 24th, Group Gp Lp Column III sold 658,440 shares of Tenaya Therapeutics stock. The shares were sold at an average price of $0.62, for a total value of $408,232.80.
• On Wednesday, February 11th, Group Gp Lp Column III sold 4,056,573 shares of Tenaya Therapeutics stock. The shares were sold at an average price of $0.68, for a total value of $2,758,469.64.
• On Tuesday, February 10th, Group Gp Lp Column III sold 343,717 shares of Tenaya Therapeutics stock. The stock was sold at an average price of $0.82, for a total value of $281,847.94.

Tenaya Therapeutics Stock Up 1.2%

Tenaya Therapeutics stock traded up $0.01 during midday trading on Thursday, hitting $0.61. The company’s stock had a trading volume of 2,393,432 shares, compared to its average volume of 3,798,919. Tenaya Therapeutics, Inc. has a 12 month low of $0.36 and a 12 month high of $2.35. The company has a market capitalization of $99.74 million, a PE ratio of -0.78 and a beta of 3.18. The stock’s 50-day moving average price is $0.73 and its 200-day moving average price is $1.14.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TNYA. Woodline Partners LP raised its position in Tenaya Therapeutics by 30,563.2% during the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock valued at $3,373,000 after acquiring an additional 5,896,873 shares in the last quarter. Empery Asset Management LP bought a new stake in Tenaya Therapeutics in the fourth quarter worth approximately $3,852,000. Vanguard Group Inc. increased its stake in shares of Tenaya Therapeutics by 6.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,064,857 shares of the company’s stock worth $8,205,000 after purchasing an additional 309,530 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Tenaya Therapeutics by 2.5% during the 4th quarter. Millennium Management LLC now owns 4,615,746 shares of the company’s stock valued at $3,284,000 after purchasing an additional 111,154 shares in the last quarter. Finally, Anson Funds Management LP bought a new position in shares of Tenaya Therapeutics during the 4th quarter valued at $2,955,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TNYA. HC Wainwright reduced their target price on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, December 12th. Morgan Stanley set a $2.00 price target on Tenaya Therapeutics in a report on Thursday, January 8th. Chardan Capital reduced their price objective on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group cut their target price on Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Tenaya Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $4.50.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno?associated virus (AAV) platform, the company aims to deliver durable, one?time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.